Ann: Phase II TACTI-002 trial recruitment successfully completed, page-67

Apolgies @theoc have tried to rack the old grey matter for PRC but failed - found these though:

'Peoples Republic of China' and 'Pre-run crap'!

On the market cap front. IMO its important that IMM is recognised for its achievements in the clinic by gradual appreciation of MC.

Why is this important other than rewarding long term SH's with options to sell for a capital gain? Noting most long termers was in pre-SP consolidation - equivalent to to 4.9c today.

Looking at the top 10 biotech buy-outs last year (from $39 - $2 billion), the average premium paid from previous day SP is only 70%.
An example of how a target ASX listed biotech SP was continuously sold down over 6 months by 50% and then BP offered 100% premium at the bottom was Viralytics. Sold for $500 million.

The argument against this is that major SH's (Ridgeback in our case for example) would never 'under sell' the real value of IMM. But I would suggest all the companies involved in above would all have major cornerstone SH's and 70% premium was good enough for them - on the assumption historical SP trajectory has been upwards.

I believe the AFR alluded to a potential opportunistic bid for Immutep due its recent fall in SP and they may not be far off the mark???